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 17/8 ± 6/168 65/6 ± 71/172 140/0 
BMI  (A5    5 ! ="(,) 09/3 ± 8/24 10/3 ± 75/24 960/0 
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ASA: American Society of Anesthesiologists; BMI: Body mass index 
050/0 < P 3: f 3 - $$ #'$ .)* -Q T, '$   
  
 2 )* +  !  ! ,-
. 
/0 .  
 
	  
 P ) 21 ( ) 
	20 ( 
 #$	± (	! %&  
() !  8(5"="   5 ! =  ( (G 
H > DI@ 9/1 ± 8/13 1/2 ± 9/12 
240/0 
H > J 5/1 ± 4/11 6/1 ± 11 
() !  K"*L I(M   5 ! =  (G 
H > DI@ 4/103 ± 6/248 9/75 ± 3/287 
310/0 
H > J 7/141 ± 3/299 7/85 ± 4/204 
"H ( () NL  (G ( 
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Abstract 
Background: Spinal surgeries are frequently complicated with high rate of intra- and post-operative 
hemorrhage. It is shown that the serum fibrinogen level is a pivotal factor in determining the degree of 
intra- and post-operative hemorrhage. This study sought to examine the effect of prophylactic infusion 
of fibrinogen in preventing hemorrhage in candidates for posterior spinal fusion surgery.  
Methods: 41 patients who were candidates for posterior spinal fusion surgery were randomly devided 
in two groups of intervention (21 patients) and control (20 patients), receiving either infusion of 
fibrinogen (1 g in 100 cc of normal saline infused within 5 minutes after induction) or placebo, 
respectively. Changes in serum hemoglobin and fibrinogen, the severity of intraoperative hemorrhage, 
and the need for blood transfusion were compared between the two groups. 
Findings: While pre- and postoperative changes in serum hemoglobin and fibrinogen did not differ 
significantly between the two groups, the mean blood loss (533.3 ± 157.9 vs. 679.0 ± 130.0 ml,  
P = 0.003) and the need for blood transfusion (0 vs. 30 percent, P = 0.030) were significantly higher in 
the control group. 
Conclusion: Prophylactic infusion of fibrinogen in candidates for posterior spinal fusion surgery may 
significantly decrease the amount of intra-operative hemorrhage and the need for blood transfusion. 
Keywords: Fibrinogen, Hemorrhage, Posterior spinal fusion surgery 
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